Institute for International Research

Know how to achieve

Main menu

My IBC

Login form

Sign Up

banner area

Find Another IBC Event

Event Search Form by Industry

De-Risking Next Generation Biologics 2009

CSS

Event Information

Capabilities & Strategies to Develop Biobetters, Biosimilars and Follow-ons

De-Risking Next Generation Biologics 2009 took place on November 12-13, 2009 at the Hyatt Regency Bethesda in Bethesda, MD. The event was enjoyed by all who participated and interest is already mounting for next year''s event. Please check back for details on the 2010 event later this year. You can purchase the presentations for this conference by contacting IBC Customer Service at 800-390-4078.

Document Title

2009 Event Wrap-Up

2009 Event Wrap-Up

This one-of-a-kind conference offered insights from leading companies about how they plan to build the capabilities to capitalize on the entire landscape of biologic products and technologies. From innovative biologics to biobetters to biosimilars, attendees learned how they planned their growth strategies to bring new products to market more quickly.

This conference is the only biologics conference on the market to discuss business strategies and market opportunities for both innovators and generics companies alike. Whether you are interested in building a business in innovative biologics, biobetters or biosimilars or protecting your innovations from upcoming patent expirations and competitor products, this must-attend conference provides you with numerous strategies and concrete ideas from industryleading companies and emerging players in this burgeoning field.

In the following sessions, over 25 speakers provided information on:

  • Strategies and business models to de-risk biologics drug development and develop a competitive edge
  • Development strategies for biobetters and improved versions of existing biologics
  • How to build technology capabilities as a strategy to share in the growing biologics market
  • The evolving market landscape of biosimilars
  • Regulatory and commercial experiences of approved biosimilars in different markets
  • Global experiences in biosimilar development: translating success to the US and Europe

Bottom menu

Copyright IBC Life Sciences, a part of Informa Life Sciences Group

Powered by Interactive Agency Janmedia Interactive, Inc.